News coverage about AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) has trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AEterna Zentaris earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 47.8689349946954 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Brokerages Set $3.50 Target Price for AEterna Zentaris Inc. (AEZS) (americanbankingnews.com)
- Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017 (finance.yahoo.com)
- Trading Watch: Chaikin Oscillator Below Zero for Aeterna Zentaris Inc (AEZS.TO) – Fairmount Times (fairmounttimes.com)
- Aeterna Zentaris’ (AEZS) CEO Michael Ward on Q3 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
- Aeterna Zentaris reports 3Q loss (finance.yahoo.com)
AEterna Zentaris (AEZS) traded down $0.05 during mid-day trading on Tuesday, reaching $2.00. 190,800 shares of the company were exchanged, compared to its average volume of 1,073,942. AEterna Zentaris has a 52-week low of $0.78 and a 52-week high of $4.25.
A number of brokerages have recently issued reports on AEZS. Maxim Group boosted their price target on shares of AEterna Zentaris from $2.00 to $4.00 and gave the stock a “buy” rating in a research note on Wednesday, July 19th. ValuEngine upgraded shares of AEterna Zentaris from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $4.33.
COPYRIGHT VIOLATION WARNING: This news story was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.chaffeybreeze.com/2017/11/14/aeterna-zentaris-aezs-receives-daily-media-sentiment-score-of-0-11.html.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.